Residency · Residency · Respirology

Solitary Pulmonary Nodule Evaluation

Definition and Epidemiology

Definition

A solitary pulmonary nodule is defined as a single, well-circumscribed, round or oval opacity measuring 3 cm or less in diameter, surrounded by aerated lung, and not associated with atelectasis, lymphadenopathy, or pleural effusion. Any lesion exceeding 3 cm is classified as a mass and carries a substantially higher probability of malignancy, warranting direct pursuit of tissue diagnosis. Pulmonary nodules are identified in 10-50% of all chest CTs, with a malignancy rate of 1-5% in screening populations and higher rates in clinical populations presenting with symptoms.

Nodule Types

Solid nodules completely obscure the underlying lung parenchyma on CT imaging. Ground glass nodules (GGN or GGO) do not obscure underlying structures, and when persistent beyond 3-6 months, often represent preinvasive lesions along the adenocarcinoma spectrum, including atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS), or invasive lepidic-predominant adenocarcinoma. Part-solid (subsolid with solid component) nodules carry the highest malignancy risk per unit volume of any nodule type, and the size of the solid component is the single best predictor of invasiveness. Calcified nodules demonstrate several recognized benign patterns including central, diffuse, popcorn, and laminated calcification, whereas eccentric or stippled calcification does not exclude malignancy.

Risk Assessment

Clinical Risk Factors

Multiple clinical factors modulate the probability of malignancy in a pulmonary nodule. Age is a significant predictor, with risk increasing substantially after age 40-50. Smoking history confers risk in a graded fashion, with current smokers at highest risk, followed by former smokers and then never-smokers. A personal history of cancer, especially an extrathoracic malignancy diagnosed within the past 5 years, increases the probability of a metastatic nodule. Family history of lung cancer in a first-degree relative, occupational exposures to carcinogens including asbestos, radon, and uranium, upper-lobe nodule location, and the presence of emphysema on CT all independently increase malignancy risk.

Radiologic Features

Size is the single most important radiologic predictor of malignancy: nodules below 6 mm carry less than 1% malignancy risk, those between 6-8 mm approximately 1-2%, those between 8-20 mm approximately 5-15%, and those exceeding 20 mm greater than 50%. Morphology provides additional discrimination: spiculated margins (the corona radiata sign) carry the highest risk, lobulated margins confer intermediate risk, and smooth margins the lowest, though smooth margins do not exclude malignancy. Growth assessment through volume doubling time (VDT) is highly informative: a VDT of 20-400 days falls within the malignant range, a VDT below 20 days suggests an infectious or inflammatory process, and a VDT exceeding 600 days is likely benign. For ground glass nodules, VDT may be very long, exceeding 800 days, and slow growth does not exclude malignancy. Density is an important predictor, with part-solid nodules carrying the highest per-nodule malignancy risk. FDG-PET avidity with an SUVmax exceeding 2.5 raises concern for malignancy, though false negatives occur with ground glass nodules, carcinoid tumors, and adenocarcinoma in situ, while false positives arise from infection and granulomatous disease.

Prediction Models

Several validated prediction models quantify the probability of malignancy. The Mayo Clinic (Swensen) model incorporates age, smoking history, cancer history, nodule size, location, and spiculation. The Brock University (PanCan) model, validated in screening cohorts, adds nodule type (solid versus subsolid), family history, and emphysema. The Herder model integrates PanCan risk assessment with PET-CT results for nodules of 8 mm or larger. These calculators should be used routinely to quantify pretest probability and guide management decisions.

<image>A visual guide to solitary pulmonary nodule morphologic features and their associated malignancy risk. Display a grid of CT nodule illustrations showing: (1) smooth, round solid nodule (low risk - benign), (2) lobulated solid nodule (intermediate risk), (3) spiculated solid nodule with corona radiata (high risk - malignant), (4) pure ground glass nodule (low risk if < 6 mm; moderate if > 6 mm persistent), (5) part-solid nodule with measurable solid component (highest risk per volume), (6) calcified nodule showing benign patterns (central, diffuse, popcorn, laminated) vs. suspicious patterns (eccentric, stippled). Include size reference markers and approximate malignancy probability percentages for each type. Label volume doubling time ranges for malignant vs. benign nodules.</image>

Management Guidelines

Fleischner Society 2017 (Incidentally Detected Solid Nodules)

For solid nodules below 6 mm, low-risk patients require no routine follow-up, while high-risk patients may undergo optional CT at 12 months. For nodules of 6-8 mm, low-risk patients should receive CT at 6-12 months with consideration of CT at 18-24 months, and high-risk patients should receive CT at 6-12 months followed by CT at 18-24 months. Nodules exceeding 8 mm warrant CT at 3 months, PET-CT, or tissue sampling depending on clinical probability assessment.

Fleischner Society 2017 (Subsolid Nodules)

Ground glass nodules below 6 mm require no routine follow-up. Ground glass nodules of 6 mm or larger should receive CT at 6-12 months followed by surveillance every 2 years for a minimum of 5 years. Part-solid nodules below 6 mm require no routine follow-up, though development of a solid component should prompt reassessment. Part-solid nodules of 6 mm or larger should receive CT at 3-6 months, and if stable with a solid component below 6 mm, annual CT for 5 years. A solid component of 8 mm or larger in a part-solid nodule carries high malignancy risk and strongly warrants tissue diagnosis or short-interval follow-up.

Lung-RADS (Screening-Detected Nodules)

Lung-RADS applies more conservative thresholds than the Fleischner Society guidelines, reflecting the lower pretest probability in screening populations. Lung-RADS 1 designates negative findings. Lung-RADS 2 indicates benign appearance or behavior. Lung-RADS 3 is probably benign and requires 6-month LDCT. Lung-RADS 4A is suspicious and warrants 3-month CT, PET, or tissue sampling. Lung-RADS 4B and 4X indicate very suspicious findings requiring additional imaging and tissue sampling.

British Thoracic Society (BTS) 2015 Guidelines

The BTS guidelines employ a risk calculator-based approach using the Brock and Herder models. A malignancy risk below 10% supports CT surveillance. A risk of 10-70% prompts PET-CT to refine the estimate using the Herder model, with subsequent management guided by post-PET risk: below 10% supports surveillance and above 10% supports tissue diagnosis or definitive treatment. A malignancy risk exceeding 70% may justify consideration of definitive treatment without biopsy following MDT discussion.

Diagnostic Procedures

PET-CT

PET-CT is most useful for solid nodules of 8 mm or larger, achieving a sensitivity of approximately 90% and specificity of approximately 75% for malignancy. False negatives are recognized with ground glass nodules, subcentimeter nodules, carcinoid tumors, adenocarcinoma in situ, minimally invasive adenocarcinoma, and mucinous adenocarcinoma. False positives occur with active infection (particularly granulomatous), inflammatory conditions, and recent biopsy sites.

CT-Guided Transthoracic Needle Biopsy

CT-guided biopsy achieves a diagnostic yield of 85-95% for malignant nodules, with lower yields for smaller and deeper lesions. The pneumothorax rate is 15-25%, with approximately 5% requiring chest tube placement. This approach is best suited for peripheral solid nodules of 10 mm or larger that are accessible to a needle trajectory.

Bronchoscopic Approaches

EBUS-TBNA is suitable for central or parabronchial lesions and enables concurrent mediastinal staging. Radial EBUS achieves a diagnostic yield of 70-80% for peripheral nodules when the lesion is visualized within the ultrasound image. Electromagnetic navigation bronchoscopy (ENB) reaches peripheral lesions beyond conventional bronchoscopic access with a yield of 60-75%, with newer platforms improving accuracy. Robotic bronchoscopy platforms (Ion, Monarch, Galaxy) offer improved peripheral reach and stability with yields of 80-90% in early reports, representing a rapidly evolving field.

Multidisciplinary Decision

Pulmonary nodule evaluation benefits from MDT discussion involving a radiologist, pulmonologist, thoracic surgeon, oncologist, and pathologist, which improves management consistency and outcomes. Patient preferences, comorbidities, life expectancy, and anxiety should be incorporated into management decisions. Not every nodule requires biopsy, and CT surveillance is appropriate for many low-risk nodules.

<image>A comprehensive management algorithm for solitary pulmonary nodule based on Fleischner and BTS guidelines. Start with nodule detected on CT. First branch: solid vs. subsolid (GGN or part-solid). For solid: size-based management (< 6 mm, 6-8 mm, > 8 mm) with risk stratification (low vs. high risk patient). For > 8 mm: show three options (CT at 3 months, PET-CT, tissue sampling) with decision factors. For subsolid: show separate algorithm for GGN and part-solid with longer follow-up periods (up to 5 years). Include a risk assessment sidebar showing Brock model factors and Herder model integration. Show procedure selection for tissue diagnosis: peripheral (CT-guided biopsy, navigational bronchoscopy, robotic bronchoscopy) vs. central (conventional bronchoscopy, EBUS). Final decision nodes: malignant (stage and treat per lung cancer guidelines), benign (discharge or continued surveillance), non-diagnostic (repeat biopsy or surgical excision).</image>

Special Considerations

Multiple Pulmonary Nodules

Fleischner guidance recommends managing multiple nodules based on the most suspicious nodule. Multiple nodules of similar size are less likely to represent metastatic disease and raise consideration of infection (particularly granulomatous), sarcoidosis, or multiple primary lung cancers. Multifocal ground glass nodules should raise consideration of multifocal adenocarcinoma spectrum disease, with each managed based on the most aggressive-appearing nodule.

Perifissural Nodules (PFN)

Perifissural nodules demonstrate a triangular or lentiform shape and are attached to or near a pulmonary fissure, typically measuring less than 10 mm. They are almost invariably benign, representing intrapulmonary lymph nodes, and require no follow-up when classic morphology is present. Both Lung-RADS and Fleischner guidelines recognize these as benign and classify them separately.

Nodule Growth Assessment

Volumetric analysis using automated or semi-automated techniques is superior to diameter-based measurement for detecting growth, as it captures three-dimensional changes more sensitively. Significant growth is defined as a volume increase of 25% or more, which corresponds to an approximately 9% increase in diameter. The NELSON trial employed volumetric assessment, defining a VDT below 400 days as a positive screen and 400-600 days as indeterminate.

Key Clinical Pearls

• Part-solid nodules have the highest per-nodule malignancy risk among all nodule types; the solid component size is the best predictor of invasive adenocarcinoma
• Persistent pure ground glass nodules >= 6 mm require long follow-up (minimum 5 years with serial CT) because they may represent very slowly growing adenocarcinoma spectrum lesions (AAH -> AIS -> MIA -> invasive)
• The Fleischner Society guidelines apply to incidentally detected nodules, NOT screening-detected nodules (use Lung-RADS for screening) and NOT in patients with known malignancy or immunocompromised patients
• PET-CT has significant false-negative rates for ground glass nodules, carcinoid, and subcentimeter lesions; a negative PET does not exclude malignancy in these scenarios
• Volumetric nodule assessment (3D volume measurement) is more sensitive than diameter-based measurement for detecting growth and should be used when available

References

1. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017;284(1):228-243.
2. Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015;70(Suppl 2):ii1-ii54.
3. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369(10):910-919. (PanCan/Brock model)
4. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial. Lancet Oncol. 2014;15(12):1332-1341.
5. American College of Radiology. Lung CT Screening Reporting & Data System (Lung-RADS) v2022. Available at: www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads.

Read this lecture as Markdown